Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, EVN (14/12/2023)

17.12.2023

Marinomed: Marinomed Biotech AG has signed a licensing agreement with Favorex, a subsidiary of DKSH and part of the Healthcare Business Unit, to commercialize a Carragelose nasal spray in Malaysia, Myanmar, Thailand and the Philippines. In addition, the European Patent Office has granted a patent covering the use of carrageenans in the prophylactic and therapeutic treatment of SARS-CoV-2 infections. This patent joins several other patents that protect the use of virus-blocking carrageenans against a range of respiratory viruses. Moreover, Marinomed was also able to successfully establish the production of Carragelose lozenges with its new Turkish manufacturing partner Meksmar. Marinomed already supplied first customers with products and plans to further expand the distribution of Carragelose lozenges in the future.
Marinomed Biotech: weekly performance: -2.40%

EVN: The weather in EVN’s three core markets during the 2022/23 financial year was characterised by milder temperatures. Revenue recorded by the EVN Group declined by 7.2% year-on-year to EUR 3,768.7m in 2022/23. This development resulted primarily from a decline in revenue in South East Europe which, in turn, was caused by lower network and energy sales volumes and by the downward trend in wholesale prices. EBITDA recorded by the EVN Group rose by 15.1% year-on-year to EUR 869.0m in 2022/23. Group net result for the 2022/23 financial year equalled EUR 529.7m (previous year: EUR 209.6m).
EVN: weekly performance: 2.95%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/12/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, EVN (14/12/2023)


17.12.2023, 1585 Zeichen



Marinomed: Marinomed Biotech AG has signed a licensing agreement with Favorex, a subsidiary of DKSH and part of the Healthcare Business Unit, to commercialize a Carragelose nasal spray in Malaysia, Myanmar, Thailand and the Philippines. In addition, the European Patent Office has granted a patent covering the use of carrageenans in the prophylactic and therapeutic treatment of SARS-CoV-2 infections. This patent joins several other patents that protect the use of virus-blocking carrageenans against a range of respiratory viruses. Moreover, Marinomed was also able to successfully establish the production of Carragelose lozenges with its new Turkish manufacturing partner Meksmar. Marinomed already supplied first customers with products and plans to further expand the distribution of Carragelose lozenges in the future.
Marinomed Biotech: weekly performance: -2.40%

EVN: The weather in EVN’s three core markets during the 2022/23 financial year was characterised by milder temperatures. Revenue recorded by the EVN Group declined by 7.2% year-on-year to EUR 3,768.7m in 2022/23. This development resulted primarily from a decline in revenue in South East Europe which, in turn, was caused by lower network and energy sales volumes and by the downward trend in wholesale prices. EBITDA recorded by the EVN Group rose by 15.1% year-on-year to EUR 869.0m in 2022/23. Group net result for the 2022/23 financial year equalled EUR 529.7m (previous year: EUR 209.6m).
EVN: weekly performance: 2.95%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/12/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #136: Formelaustria Young Driver Programme als Investment, Kart-Talente & Sim-Racer zu F4-Racern machen




 

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, Semperit, Austriacard Holdings AG, Addiko Bank, Immofinanz, Verbund, VIG, CA Immo, Flughafen Wien, Uniqa, AT&S, Cleen Energy, Kostad, Porr, Wolford, Oberbank AG Stamm, UBM, DO&CO, Agrana, Amag, Erste Group, EVN, OMV, Palfinger, Österreichische Post, S Immo, Telekom Austria, Wienerberger, Zalando, SAP.


Random Partner

Verbund
Verbund ist Österreichs führendes Stromunternehmen und einer der größten Stromerzeuger aus Wasserkraft in Europa. Mit Tochterunternehmen und Partnern ist Verbund von der Stromerzeugung über den Transport bis zum internationalen Handel und Vertrieb aktiv. Seit 1988 ist Verbund an der Börse.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten